Hypoxen / OlifenГипоксен / Олифен
Sodium polydihydroxyphenylene thiosulfonate, a synthetic sulfur-containing polymer formerly called Olifen. Researchers studied its effects under low-oxygen conditions.
What the studies found
Comparison in people · 2009
Psychological and psychomotor changes during heat exposure
- Hypoxen · heat
- Favorable subjective and mental work measures describedNo numerical effect, duration or arm sizes in the abstract.
- Other arms
- Different patterns under cold, heat and simulated altitudeCytoflavin, Reamberin and Mexidol are distinct comparators.
In a chamber study of healthy young men, Hypoxen was associated with psychological and psychomotor responses during heat exposure. Effects differed across drugs and environments.
Study notes · methods, sources and limitations
Participants or model Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia
Design Healthy men aged 20–24 in the Tabai thermobaric chamber; Hypoxen, Cytoflavin, Reamberin and Mexidol.
Important limitations
- Noopept was not one of the tested drugs. Comparator allocation, effect sizes and adverse-event reporting require full-text review.
- Preliminary chamber results. The authors’ recommendations are not verified worker protection.
Eksp Klin Farmakol. 72(6):36–41 · Indexed abstract
Animal research · 2021
Hypoxen: positive cold comparison, uncertain heat result
Study of multiple preparations
- Hypoxen · hypoxia plus cold
- 10.0±0.9 versus 4.5±0.4 s; +120%Table 3; compared with stressed controlp=3×10⁻⁵
- Hypoxen · hypoxia plus heat
- 22.7±3.5 versus 16.9±2.3 s; +34%Table 1; nonsignificant versus stressed controlp=0.18
In a mouse model, the Hypoxen cold result was significant; heat result was not. VIR-8 and the other groups are separate comparators.
Study notes · methods, sources and limitations
Participants or model Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
Design Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
- Reported study exposure
- 50 mg/kg orally, once 1 hour before testing.
Important limitations
- No verified human protection from environmental stress.
- Each comparator used its own formulation, dose and schedule. The short mouse swim endpoint cannot establish human cold tolerance, prevention of heat injury or improved sports performance. The paper does not identify VIR-8 sequences or establish an identity match with PPK-V.
- Retain the neutral heat result alongside the positive cold result. The model examines hemic hypoxia during temperature stress, not altitude acclimatization or actual outdoor work. The distinct products cannot be ranked as equivalent-dose interventions.
Biomeditsina. 17(1):57–69 · Original journal article
Lab research · 2010
The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases
Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.
Study notes · methods, sources and limitations
Participants or model Isolated rat liver mitochondria
Important limitations
- Isolated organelles and experimental concentrations do not establish effects of oral use in humans. The translation and Russian paper are the same experiment.
Izv Akad Nauk Ser Biol. (4):411–416; English translation Biology Bulletin 37:346–350 · Indexed abstract
About Hypoxen / Olifen
Names in this research collection
Hypoxen · Hypoxenum · Gipoksen · Olifen · Олифен · Гипоксен · Polyfen · Polifen · Biotop · sodium polydihydroxyphenylene thiosulfonate
Identity / background source ↗
Research background
A synthetic polyphenolic preparation studied in hypoxia, environmental stress, exercise and cellular-energy metabolism. Human findings are limited, and laboratory effects depend on experimental conditions.
Russian ME/CFS and fatigue research ↗
More study findings
Study involving people · 2004
Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents
- Result availability
- Numerical results not recoveredOriginal paper needed to verify the preparation, protocol, sample and effect size.
An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.
Study notes · methods, sources and limitations
Participants or model Athletes; sample and allocation not recovered
Design Historical athlete bioenergetics publication.
Important limitations
- Clinical Trial indexing does not establish randomization or methodological quality. Russian and English versions are one publication, not two studies.
- Only the citation is available. It gives no measured outcome.
Fiziologiya Cheloveka. 30(2):101–109; English translation: Human Physiology 30:216–223 · Bibliographic lead
Animal research · 2002
Injection and oral pretreatment produced different results
Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.
Study notes · methods, sources and limitations
Participants or model C57BL/6 mouse bone-marrow chromosome-aberration assay
Important limitations
- Route- and timing-dependent results; the oral negative finding must be retained. A mouse mutagen assay does not establish protection against industrial gases, benzene or cancer.
Experimental and Clinical Pharmacology. 65(3):54–56 · Indexed abstract
Performance research in context
Sports performance evidence map ↗ Military & occupational evidence map ↗
- Compound class
- Polymeric antihypoxant
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Environmental and clinical comparisons; limited methodological detail
Study methods
Human comparisons, rat studies, mitochondrial assays and analytical chemistry
Independent replication
Independent clinical confirmation remains limited; historical cohorts may overlap
Source access
Indexed abstracts, publisher records, patent text and explicit archival leads
Safety evidence
Long-term and combination safety not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2021
VIR-8, Hypoxen and comparators under hypoxia with heat or cold
In a mouse model, the Hypoxen cold result was significant; heat result was not. VIR-8 and the other groups are separate comparators.
Study notes and original source
VIR-8, Hypoxen and comparators under hypoxia with heat or cold
VIR-8 is a separately named polypeptide complex from Mobitek-M. Hypoxen, trimetazidine and food preparations were distinct arms. · Original journal article
Format: Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked · Reviewed: Reported methods, results and evidence limitations
E. B. Shustov, Yu. V. Fokin, S. L. Lyublinskiy, O. V. Alimkina, A. E. Kim, D. Yu. Ivkin, E. L. Matveenko, A. S. Ivkina, G. A. Plisko, M. A. Poveryaeva · Biomeditsina. 17(1):57–69
VIR-8 extended swimming under hypoxia plus cold (12.5±1.3 vs 4.5±0.4 seconds) but did not improve swimming under hypoxia plus heat (16.8±1.5 vs 16.9±2.3 seconds).
Results and tables
Reported findings and study design
VIR-8 extended swimming under hypoxia plus cold (12.5±1.3 vs 4.5±0.4 seconds) but did not improve swimming under hypoxia plus heat (16.8±1.5 vs 16.9±2.3 seconds).
Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
Population or model Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
Dose, route and schedule
VIR-8: 5 mg/kg rectally in 0.5 mL starch vehicle daily for 5 days. Hypoxen: 50 mg/kg orally by gavage once, 1 hour before testing. Sodium nitrite: 50 mg/kg intraperitoneally for hemic hypoxia. Main swim load: 5% body mass.
Protocol source ↗ · Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| VIR-8 · hypoxia plus cold | 12.5±1.3 versus 4.5±0.4 s; +178% | Table 3; compared with stressed control, n=10 per group · p=0.0002 |
| VIR-8 · hypoxia plus heat | 16.8±1.5 versus 16.9±2.3 s; 0% reported | Table 1; compared with stressed control · p=0.99 |
| VIR-8 · hypoxia at normal temperature | 29.8±4.2 versus 24.4±2.7 s | Tables 1 and 3 show the same thermoneutral series. |
| Hypoxen · hypoxia plus cold | 10.0±0.9 versus 4.5±0.4 s; +120% | Table 3; compared with stressed control · p=3×10⁻⁵ |
| Hypoxen · hypoxia plus heat | 22.7±3.5 versus 16.9±2.3 s; +34% | Table 1; nonsignificant versus stressed control · p=0.18 |
| Other arms · directional reversal | Flamenco 50 mg/kg: −37% in heat, +111% in cold | Different comparator preparation; not a VIR-8 result. Low-dose heat comparison p=0.02; cold p=2×10⁻¹² as printed. |
| Safety and sequence | No human safety study or sequence-level characterization reported | The designation VIR-8 is insufficient to infer constituent peptides. |
Tables 1 and 3 · forced swimming across stress conditions
| Group | Hypoxia, normal temperature (s) | Hypoxia + heat (s) | Heat effect vs control | Hypoxia + cold (s) | Cold effect vs control |
|---|---|---|---|---|---|
| Intact comparator | 72.6±7.0 | 63.5±7.9 | — | 5.6±0.7 | — |
| Stressed control | 24.4±2.7 | 16.9±2.3 | Reference | 4.5±0.4 | Reference |
| MioActive Sport | 24.8±2.7 | 16.9±1.3 | +2%; p=0.99 | 18.4±1.5 | +308%; p=2×10⁻¹¹ |
| VIR-8 | 29.8±4.2 | 16.8±1.5 | 0%; p=0.99 | 12.5±1.3 | +178%; p=0.0002 |
| Flamenco 50 mg/kg | 19.3±1.5 | 10.6±0.9 | −37%; p=0.02 | 9.5±1.1 | +111%; p=2×10⁻¹² |
| Flamenco 75 mg/kg | 21.5±5.0 | 14.6±1.8 | −14%; p=0.43 | 12.9±0.8 | +187%; p=2×10⁻¹⁰ |
| Flamenco 250 mg/kg | 20.7±2.8 | 34.4±4.7 | +104%; p=0.003 | 6.9±1.0 | +53%; p=2×10⁻¹² |
| Trimetazidine | 22.7±11.1 | 87.3±18.2 | +418%; p=0.01 | 6.7±0.3 | +49%; p=2×10⁻¹⁷ |
| Hypoxen | 30.1±4.3 | 22.7±3.5 | +34%; p=0.18 | 10.0±0.9 | +120%; p=3×10⁻⁵ |
M±m and reported p-values transcribed from the article. Percentages are the authors’ reported changes relative to stressed controls, not comparisons between active arms. The intact groups do not receive hemic hypoxia; the displayed first column represents the relevant normothermic baseline.
Retain the neutral heat result alongside the positive cold result. The model examines hemic hypoxia during temperature stress, not altitude acclimatization or actual outdoor work. The distinct products cannot be ranked as equivalent-dose interventions.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
- Source reviewed
- Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked
Study limitations
- Each comparator used its own formulation, dose and schedule.
- The short mouse swim endpoint cannot establish human cold tolerance, prevention of heat injury or improved sports performance.
- The paper does not identify VIR-8 sequences or establish an identity match with PPK-V.
Reviewed 2026-11-08.
Experiment described in a patent · 2003
Hypoxen: complement-pathway inhibition lead — RU2205002C1
The experiments support a complement-interaction hypothesis rather than established clinical immune control.
C1q-related activity · Concentration-dependent inhibition of C1q-associated activity reported · Laboratory complement system, not autoimmune disease activity
Study notes and original source
Hypoxen: complement-pathway inhibition lead — RU2205002C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Б.Б. Шойбонов, А.Н. Онтобоев, А.А. Зинченко, В.А. Алёшкин · RU2205002C1 · patent family 20255843
The experiments support a complement-interaction hypothesis rather than established clinical immune control.
Results and tables
Reported patent results
Findings described in words
The experiments support a complement-interaction hypothesis rather than established clinical immune control.
Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.
Population or model Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| C1q-related activity | Concentration-dependent inhibition of C1q-associated activity reported | Laboratory complement system, not autoimmune disease activity |
| Affinity-value ambiguity | The indexed text has an unclear exponent in the stated affinity value; no corrected binding constant is entered | An OCR/exponent problem can change the value by many orders of magnitude |
A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.
- A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Review of earlier studies · 2025
A review of Hypoxen pharmacology and potential to enhance sports performance
The review identifies a difficult-to-access Military Medical Academy literature from the 1980s–1990s and limited human evidence. It discusses several mitochondrial mechanisms rather than establishing a single oxygen-boosting effect.
Study notes and original source
A review of Hypoxen pharmacology and potential to enhance sports performance
Format: Journal article · Reviewed: Abstract reviewed
K. Jędrejko, O. Catlin, R. Faiss, A. Pokrywka · Drug Testing and Analysis. 17(10):1896–1911
The review identifies a difficult-to-access Military Medical Academy literature from the 1980s–1990s and limited human evidence. It discusses several mitochondrial mechanisms rather than establishing a single oxygen-boosting effect.
- Population / setting
- Review of historical, experimental and human literature
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- A literature review is not independent replication.
- The authors report a lack of clinical trials meeting international standards; historical use does not establish effectiveness or safety.
Reviewed 2026-10-04.
Study involving people · 2004
Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents
An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.
Study notes and original source
Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents
Format: Journal article · Reviewed: Bibliographic metadata only
N. D. Altukhov, N. I. Volkov, S. L. Khoronyuk · Fiziologiya Cheloveka. 30(2):101–109; English translation: Human Physiology 30:216–223
An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.
Results and tables
Reported findings and study design
Historical athlete bioenergetics publication.
Population or model Athletes; sample and allocation not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Result availability | Numerical results not recovered | Original paper needed to verify the preparation, protocol, sample and effect size. |
Only the citation is available. It gives no measured outcome.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Athletes; sample and allocation not recovered
- Source reviewed
- PubMed citation checked; full text and results not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
- Clinical Trial indexing does not establish randomization or methodological quality.
- Russian and English versions are one publication, not two studies.
Reviewed 2026-10-04.
Animal research · 2008
Accelerated utilization of lactate under the effect of hypoxen after intensive exercise
Hypoxen combined with energy-metabolism substrates was associated with higher lactate during maximal exercise, faster subsequent utilization and a lower recovery lactate/pyruvate ratio. The authors also describe an in-vitro NADH-oxidation pathway involving cytochrome c.
Study notes and original source
Accelerated utilization of lactate under the effect of hypoxen after intensive exercise
Format: Journal article · Reviewed: Abstract reviewed
E. V. Grishina, Ya. V. Khaustova, V. G. Pogorelova, A. G. Pogorelov, M. K. Kuzmich, E. I. Maevskii · Bulletin of Experimental Biology and Medicine. 145(2):198–201
Hypoxen combined with energy-metabolism substrates was associated with higher lactate during maximal exercise, faster subsequent utilization and a lower recovery lactate/pyruvate ratio. The authors also describe an in-vitro NADH-oxidation pathway involving cytochrome c.
- Population / setting
- Exercise experiment plus mitochondrial assays; in-vivo sample not specified in accessible abstract
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised. Study type is based on the database record and abstract, where available.
Study limitations
- Combination exposure cannot isolate Hypoxen’s contribution.
- The abstract does not establish the in-vivo species, sample, allocation or safety. This is not presented as a verified human recovery trial.
Reviewed 2026-10-04.
Lab research · 2010
The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases
Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.
Study notes and original source
The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases
Format: Journal article · Reviewed: Abstract reviewed
E. A. Kosenko, M. B. Abramova, N. I. Venediktova, I. I. Popova, Yu. G. Kaminskii · Izv Akad Nauk Ser Biol. (4):411–416; English translation Biology Bulletin 37:346–350
Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.
- Population / setting
- Isolated rat liver mitochondria
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- Isolated organelles and experimental concentrations do not establish effects of oral use in humans.
- The translation and Russian paper are the same experiment.
Reviewed 2026-10-04.
Lab research · 2010
Effect of Hypoxen on bioenergetic processes in mitochondria and ATP-sensitive potassium-channel activity
At low experimental concentrations, the authors report increased respiration, coupling, hydrogen-peroxide formation and potassium-associated mitochondrial swelling. ATP-related responses led them to propose involvement of mitochondrial ATP-sensitive potassium channels.
Study notes and original source
Effect of Hypoxen on bioenergetic processes in mitochondria and ATP-sensitive potassium-channel activity
Format: Journal article · Reviewed: Abstract reviewed
S. V. Murzaeva, M. B. Abramova, I. I. Popova, E. N. Gritsenko, G. D. Mironova, E. I. Lezhnev · Biofizika. 55(5):814–821; English translation Biophysics 55:727–732
At low experimental concentrations, the authors report increased respiration, coupling, hydrogen-peroxide formation and potassium-associated mitochondrial swelling. ATP-related responses led them to propose involvement of mitochondrial ATP-sensitive potassium channels.
- Population / setting
- Isolated rat heart and liver mitochondria
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- Concentration, substrate and tissue differ from the respiration-inhibition experiments.
- Increased peroxide formation complicates a simple antioxidant narrative; these assays do not establish clinical benefit.
Reviewed 2026-10-04.
Comparison in people · 2012
Impact of Hypoxen therapy on postoperative course in gynecologic patients
An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.
Study notes and original source
Impact of Hypoxen therapy on postoperative course in gynecologic patients
Format: Journal article · Reviewed: Abstract reviewed
M. Z. Dugieva, K. V. Kotenko, K. V. Morozova · Antibiotiki i Khimioterapiya. 57(5–6):28–31
An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.
Results and tables
Reported findings and study design
An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.
52 Hypoxen recipients versus 339 routine-care controls after laparotomic gynecological surgery.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Prolonged postoperative pain | Lower reported proportion | Hypoxen + routine care versus routine care · Early postoperative period · p<0.05, χ² test |
| Lipid oxidation and antioxidant measures | Reported improvement; no numerical marker values in abstract | |
| Group sizes | 52 adjunctive; 339 routine care |
Unequal, non-randomized groups and absent event counts prevent calculation of absolute pain reduction or number needed to treat.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 52 adjunct-Hypoxen patients and 339 routine-care controls after abdominal gynecologic surgery
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- Very unequal group sizes; randomization, blinding and baseline comparability are not established.
- No absolute pain-event counts in the abstract. Surgical findings do not establish sports, occupational or long-term safety benefits.
Reviewed 2026-11-01.
Animal research · 2002
Antimutagenic Hypoxen activity in vivo
Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.
Study notes and original source
Antimutagenic Hypoxen activity in vivo
Format: Journal article · Reviewed: Abstract reviewed
O. A. Karpova, L. V. Mikhina, A. A. Denisov, M. K. Kuzmich · Experimental and Clinical Pharmacology. 65(3):54–56
Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.
- Population / setting
- C57BL/6 mouse bone-marrow chromosome-aberration assay
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- Route- and timing-dependent results; the oral negative finding must be retained.
- A mouse mutagen assay does not establish protection against industrial gases, benzene or cancer.
Reviewed 2026-10-04.
Animal research · 2012
Influence of Metaprot and Hypoxen on inflammatory-reaction development in an experiment
Hypoxen and Metaprot showed weak anti-inflammatory activity alone but enhanced aspirin-associated effects. The publisher abstract identifies Hypoxen plus aspirin as the most effective combination tested.
Study notes and original source
Influence of Metaprot and Hypoxen on inflammatory-reaction development in an experiment
Format: Journal article · Reviewed: Abstract reviewed
V. E. Novikov, S. A. Ilyukhin, E. V. Pozhilova · Reviews on Clinical Pharmacology and Drug Therapy. 10(4):63–66
Hypoxen and Metaprot showed weak anti-inflammatory activity alone but enhanced aspirin-associated effects. The publisher abstract identifies Hypoxen plus aspirin as the most effective combination tested.
- Population / setting
- Carrageenan-induced rat paw inflammation
- Source reviewed
- Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
- Animal inflammation endpoints are not human analgesic or performance outcomes.
- The abstract wording does not establish a Hypoxen-plus-Bemitil performance regimen. Full arm definitions and safety require review.
Reviewed 2026-10-04.
Animal research · 2004
Physiological mechanisms of chronic exposure to sulfur-containing gas in an experiment
The author’s conclusions report lower lipid-peroxidation, hypoxia and endogenous-intoxication markers and a shorter recovery period with Olifen. The industrial-gas context concerns the Astrakhan program, but the intervention evidence here is animal work.
Study notes and original source
Physiological mechanisms of chronic exposure to sulfur-containing gas in an experiment
Format: Dissertation abstract reproduction · Reviewed: Relevant conclusions and catalogue checked
I. A. Bednov · Candidate biological-sciences dissertation, Astrakhan, 143 pages; author-abstract reproduction
The author’s conclusions report lower lipid-peroxidation, hypoxia and endogenous-intoxication markers and a shorter recovery period with Olifen. The industrial-gas context concerns the Astrakhan program, but the intervention evidence here is animal work.
- Population / setting
- Rats exposed chronically to sulfur-containing gas standardized to 3 mg/m³ hydrogen sulfide
- Source reviewed
- Online author-abstract reproduction reviewed; original experimental tables remain to be recovered.
Study limitations
- Author-abstract transcription, not the full 143-page dissertation.
- Mixed industrial gas is not equivalent to pure H₂S or benzene; no protective effect in exposed workers is established.
Reviewed 2026-10-04.
Experiment described in a patent · 2005
Method of pharmacological correction of human work capacity in extreme situations
The patent organizes pharmacological support before exposure, during work and after work. It names Hypoxen, Sydnocarb, Mebix, Deltoran and ascorbate in the first phases, with symptom-dependent changes.
Study notes and original source
Method of pharmacological correction of human work capacity in extreme situations
Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
E. G. Zhilyaev, P. M. Shalimov, D. V. Glukhov, A. G. Zhilyaev, S. E. Makarov, G. G. Neznamov · EA005383B1. Filed 28 December 2001; published 24 February 2005. Center for Extreme Medicine
The patent organizes pharmacological support before exposure, during work and after work. It names Hypoxen, Sydnocarb, Mebix, Deltoran and ascorbate in the first phases, with symptom-dependent changes.
Results and tables
Reported patent results
The patent gives no measured outcomes
The accessed disclosure specifies a scheme but does not supply an extractable treatment cohort or measured comparative outcomes.
A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.
Population or model A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical or performance results | No participant denominator, endpoint values or controlled effect estimate reported in the accessed description | The claimed effectiveness is not a measured result |
Hypoxen is one component of a proposed multi-agent approach. A regimen and its claimed benefits cannot be substituted for experimental or clinical data.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.
- Source reviewed
- Claims, description, filing dates and prior-art citation reviewed.
Study limitations
- A patent documents a proposal, not a validated regimen, implemented service-wide doctrine or controlled trial.
- The document cites a 1999 Academy publication by Novikov and Shustov. Its full text is unavailable here.
Reviewed 2026-11-06.
Laboratory analysis · 2025
Urinary metabolites indicative of Hypoxen administration monitored by LC–HRMS/MS
The analytical study identified eight plausible Hypoxen-related urinary analytes. It provides markers for detecting administration, not evidence of improved endurance or clinical effectiveness.
Study notes and original source
Urinary metabolites indicative of Hypoxen administration monitored by LC–HRMS/MS
Format: Journal article · Reviewed: Publisher methods and results reviewed
C. Görgens, T. Möller, S. Guddat, and colleagues · Drug Testing and Analysis. 17(2):225–230; first published online 23 April 2024
The analytical study identified eight plausible Hypoxen-related urinary analytes. It provides markers for detecting administration, not evidence of improved endurance or clinical effectiveness.
- Population / setting
- Exploratory post-administration urine analysis
- Source reviewed
- Publisher analytical report reviewed; chemical assignments are reported at the authors’ stated certainty.
Study limitations
- Tentative metabolite assignments and exploratory sampling limit interpretation.
- Detection of use is distinct from proof of efficacy, safety or a doping-rule violation.
Reviewed 2026-10-04.
Comparison in people · 2014
Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]
An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.
Study notes and original source
Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]
Kundashev UK, Zurdinov AZ, Barchukov VG · Eksperimental'naia i klinicheskaia farmakologiia 77(9):32-37. PMID 25365868
An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.
Results and tables
Reported findings and study design
An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.
Volunteers acclimatized for 15 days at 1,670 m before moving to 3,750 m; group sizes not supplied.
Population or model Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Adaptation timing | Combination: within first hours; Hypoxen: by day 3; placebo: still developing on day 3 | Authors’ descriptive metabolic time course, not a timed endurance effect |
| Exercise tolerance and blood-cell measures | Reported stronger responses with the combination | No absolute work or blood-cell effect sizes supplied |
| Studied arms | Metaprot 0.125 g + Ladasten 0.1 g; Hypoxen 0.5 g; placebo | Combination effect cannot be assigned to either component alone |
No component-only arms are described in the abstract. Earlier metabolic adaptation does not establish safe high-altitude use or independent bromantane efficacy.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- No single-component arms are described, so the study cannot isolate contributions or establish synergy.
- Enrollment and allocation details require full-text review.
- Not a validated altitude-illness prevention strategy.
Reviewed 2026-11-01.
Comparison in people · 2009
Meteoadaptogenic properties of antihypoxants
In a chamber study of healthy young men, Hypoxen was associated with psychological and psychomotor responses during heat exposure. Effects differed across drugs and environments.
Study notes and original source
Meteoadaptogenic properties of antihypoxants
V. P. Ganapolsky, P. D. Shabanov · Eksp Klin Farmakol. 72(6):36–41
The healthy-volunteer chamber comparison reports environment-dependent effects. Hypoxen was associated with psychological and psychomotor responses during heat exposure; benefits were not uniform across the four agents and three environments.
Results and tables
Reported findings and study design
Healthy men aged 20–24 in the Tabai thermobaric chamber; Hypoxen, Cytoflavin, Reamberin and Mexidol.
Population or model Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hypoxen · heat | Favorable subjective and mental work measures described | No numerical effect, duration or arm sizes in the abstract. |
| Other arms | Different patterns under cold, heat and simulated altitude | Cytoflavin, Reamberin and Mexidol are distinct comparators. |
Preliminary chamber results. The authors’ recommendations are not verified worker protection.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia
- Source reviewed
- Russian primary-publisher abstract and DOI checked; full text not reviewed.
Study limitations
- Noopept was not one of the tested drugs.
- Comparator allocation, effect sizes and adverse-event reporting require full-text review.
Reviewed 2026-10-04.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗